| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.096 | 0.01 |
| mRNA | CCT007093 | GDSC1000 | pan-cancer | AAC | -0.087 | 0.01 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.01 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | -0.093 | 0.01 |
| mRNA | Topotecan | CTRPv2 | pan-cancer | AAC | 0.082 | 0.01 |
| mRNA | SR1001 | CTRPv2 | pan-cancer | AAC | -0.095 | 0.01 |
| mRNA | ceranib-2 | CTRPv2 | pan-cancer | AAC | 0.082 | 0.01 |
| mRNA | linifanib | CTRPv2 | pan-cancer | AAC | 0.088 | 0.01 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.073 | 0.02 |
| mRNA | SNX-2112:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.079 | 0.02 |